Upper-normal blood pressures in otherwise healthy middle-aged men are long-term predictors of incident atrial fibrillation in older age, according to a study that appeared online January 17 in Hypertension.
Upper-normal blood pressures (BP) in otherwise healthy middle-aged men are long-term predictors of incident atrial fibrillation (AF) in older age, according to a study that appeared online January 17 in Hypertension. The study was conducted by a Swedish group led by Irene Grundvold, Department of Cardiology, Oslo University Hospital, Norway.
Researchers recruited 2,014 healthy middle-aged men from 1972 to 1975. They underwent a comprehensive clinical examination, including BP measurements. During up to 35 years of follow-up, 270 men were found to have developed AF. The majority of these developed the condition late in life, on average 20 years from baseline.
Men with baseline systolic BP ≥140 mm Hg and upper-normal BP 128 to 138 mm Hg had 1.60-fold (95% CI, 1.15–2.21) and 1.50-fold (1.10–2.03) risk of AF, respectively, compared with men with BP <128 mm Hg. Baseline diastolic BP ≥80 mm Hg increased the risk of incident AF 1.79-fold (95% CI, 1.28–2.59) compared with diastolic BP <80 mm Hg.
When adjusting for the occurrence of diabetes mellitus or cardiovascular diseases before an AF event, the results still maintained significance. Additional analyses, on average 7 years after baseline, including men still healthy, showed that sustained upper-normal systolic BP remained a significant predictor of subsequent AF.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More